US › Healthcare

Fortress Biotech Inc (FBIO)

US · Healthcare · Biotechnology

$2.72-1.45%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$16.0M
Revenue YoY
+22.1%
Net profit
$110.4M
Profit YoY
+1142.8%
EPS
$2.82
EPS estimate
$-0.22
Net margin
688.2%

EPS came in at 2.82 against a street estimate of -0.22 — a beat of 1381.8%.

Key statistics

Market cap
$104.0M
P/E
1.0
Forward P/E
1.3
P/B
0.64
Book value
$4.89
EPS (TTM)
$3.24
52-week high
$4.53
52-week low
$1.81
50-day MA
$3.05
200-day MA
$2.98
Beta
1.21

Analyst view

Analysts rate Fortress Biotech Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $11.00.

Shareholding

Insiders
22.79%
Institutions
24.72%

Largest institutional holders

FundStake
Opaleye Management Inc3.14%
Vanguard Capital Management, LLC2.91%
Shikiar Asset Management Inc0.92%
Geode Capital Management, LLC0.87%
GSA Capital Partners LLP0.77%
Northern Trust Corp0.69%
Susquehanna International Group, LLP0.63%
BlackRock Inc0.59%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Fortress Biotech Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.